Semaglutide or Placebo for Nonalcoholic Steatohepatitis. Reply

N Engl J Med. 2021 Jul 8;385(2):e6. doi: 10.1056/NEJMc2106921.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Glucagon-Like Peptides / therapeutic use
  • Humans
  • Hypoglycemic Agents / therapeutic use
  • Non-alcoholic Fatty Liver Disease* / drug therapy

Substances

  • Hypoglycemic Agents
  • semaglutide
  • Glucagon-Like Peptides